<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-NF18WQ7A</identifier><date>2015</date><creator>Dolžan, Vita</creator><creator>Kores-Plesničar, Blanka</creator><creator>Terzič, Tea</creator><relation>documents/doc/N/URN_NBN_SI_doc-NF18WQ7A_001.pdf</relation><relation>documents/doc/N/URN_NBN_SI_doc-NF18WQ7A_001.txt</relation><format format_type="issue">5</format><format format_type="volume">66</format><format format_type="type">article</format><format format_type="extent">str. 402-406</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID">29122343</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-NF18WQ7A</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">genetska variabilnost</subject><subject language_type_id="slv">polimorfizem</subject><subject language_type_id="slv">shizofrenija</subject><subject language_type_id="eng">therapy</subject><subject language_type_id="slv">zdravljenje</subject><title>CYP3A4 rs35599367 ne vpliva na zdravljenje z antipsihotiki pri slovenskih bolnikih s shizofrenijo</title><title>CYP3A4 rs35599367 does not influence antipsychotic treatment in Slovenian patients with schizophrenia</title></Record>